CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Everolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02352844
NCT02352844Phase 2Completed
CompareCT.gov

Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Washington University School of Medicine·interventional·Posted Feb 2, 2015·Updated Oct 2, 2018

In Brief

A Phase 2 clinical trial evaluating Everolimus for Solid Malignancy and Solid Tumor. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this research study is to look at participants with solid tumor malignancies and specific mutations respond to treatment with everolimus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Malignancy, Solid Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2, 2015
Enrollment StartOct 7, 2015
Primary CompletionAug 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.4 years ago

Interventions

Everolimusdrug